Survodutide: difference between revisions
Diff·revision 9 → 10·02:07, 12 Mar 2025
Difference between revision 9 and revision 10 of Survodutide. 8 lines changed; the page grew by 465 bytes.
| Revision 9 — 17:46, 25 Feb 2025 ArchiveBot (talk) bot: add drug-class category 4,005 bytes +32 | Revision 10 — 02:07, 12 Mar 2025 AmylinAmos (talk) expand §Design and rationale 4,470 bytes +465 | ||
|---|---|---|---|
| 26 | A separate phase 2 trial in biopsy-confirmed metabolic dysfunction-associated steatohepatitis reported improvement in histological endpoints at 48 weeks. Histological endpoints in that condition are notoriously variable between readers, and the trial's own reporting acknowledges the limitation. | 26 | A separate phase 2 trial in biopsy-confirmed metabolic dysfunction-associated steatohepatitis reported improvement in histological endpoints at 48 weeks. Histological endpoints in that condition are notoriously variable between readers, and the trial's own reporting acknowledges the limitation. |
| 27 | 27 | ||
| + | 28 | Gastrointestinal adverse events dominated and were dose-related. A heart-rate increase attributable to the glucagon component was reported, as it was for retatrutide, and rises in fasting glucose were observed early in escalation in some participants — the anticipated consequence of glucagon agonism outpacing GLP-1 agonism at low total dose.{{r|zimmermann2022}} | |
| + | 29 | ||
| 28 | == References == | 30 | == References == |
| 29 | {{reflist}} | 31 | {{reflist}} |
| ⋮ | ⋮ | ||
| 31 | <ref name="blueher2024">Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. "Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist." ''Diabetologia'' 67(3):470–482 (2024). PMID 38095713.</ref> | 33 | <ref name="blueher2024">Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. "Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist." ''Diabetologia'' 67(3):470–482 (2024). PMID 38095713.</ref> |
| 32 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> | 34 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> |
| + | 35 | ||
| + | 36 | == See also == | |
| + | 37 | * [[Retatrutide]] | |
| + | 38 | * [[Glucagon]] | |
| + | 39 | * [[Dual incretin agonist]] | |
| + | 40 | * [[Efinopegdutide]] | |
| 33 | 41 | ||
| 34 | {{DEFAULTSORT:Survodutide}} | 42 | {{DEFAULTSORT:Survodutide}} |